Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

BACKGROUND: Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechalle...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Immunother Cancer
मुख्य लेखकों: Siddiqui, Bilal A, Gheeya, Jinesh S, Goswamy, Rohit, Bathala, Tharakeswara K, Surasi, Devaki Shilpa, Gao, Jianjun, Shah, Amishi, Campbell, Matthew T, Msaouel, Pavlos, Goswami, Sangeeta, Wang, Jennifer, Zurita, Amado J, Jonasch, Eric, Corn, Paul G, Aparicio, Ana M, Siefker-Radtke, Arlene O, Sharma, Padmanee, Subudhi, Sumit K, Tannir, Nizar
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMJ Publishing Group 2021
विषय:
Clinical/Translational Cancer Immunotherapy
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://ncbi.nlm.nih.gov/pubmed/34326169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002850
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन